Evidence map›Paper›PMID 36938088›Full record

ArticleKidney international reports2023

Characteristics of Renal Intravascular Large B-cell Lymphoma.

Prerna Rastogi, Audai Alrwashdeh, Tiffany Caza, Mercury Lin, Mohammad Obeidat, Gabriel Giannini, Chris Larsen, Dao-Fu Dai

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Prerna RastogiDepartment of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Audai AlrwashdehDepartment of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Tiffany CazaArkana Laboratories, Little Rock, Arkansas, USA.
Mercury LinDepartment of Pathology and Laboratory Medicine, Cedars Sinai, Los Angeles, California, USA.
Mohammad ObeidatDepartment of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Gabriel GianniniArkana Laboratories, Little Rock, Arkansas, USA.
Chris LarsenArkana Laboratories, Little Rock, Arkansas, USA.
Dao-Fu DaiDepartment of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
University of Iowa Hospitals and Clinics · USArkana Laboratories · USCedars-Sinai Medical Center · US

Funding

Metabolic reprogramming and FGF21 signaling in kidney health and polycystic kidney diseasesR01DK133118 · NIDDK · UNIVERSITY OF IOWA · PI Dao-Fu Dai · 2022 to 2026
$2.0M
The role of energy sensor signaling in mitochondrial cardiomyopathyK08HL145138 · NHLBI · UNIVERSITY OF IOWA · PI DAI, DAO-FU · 2019 to 2023
$803k
NHLBI NIH HHS K08 HL145138NIDDK NIH HHS R01 DK133118
6 · The paper itself

Abstract

Introduction: Renal intravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive B-cell lymphoma with neoplastic cells occupying the vascular lumina with only 53 patients reported to date. Here, we present the largest case series to characterize this rare disease. Methods: We performed a multi-institutional, retrospective review of kidney biopsies and autopsies with a diagnosis of kidney IVLBCL and report our findings. Results: We identified 20 patients with an average age of 65.7 ± 7.8 years (55% males) with IVLBCL on kidney biopsy. The most common clinical presentation was fever and anemia. Acute kidney injury (AKI) was noted in 70% to 90%, proteinuria in 70% to 84.1%, hematuria in 45%, and nephrotic-range proteinuria in 10% to 26.1% of cases. The median (interquartile range) of serum creatinine was 1.75 (1.14, 3.3) mg/dl. Neoplastic lymphoid cells were present in glomeruli, peritubular capillaries, and arteries or veins. Of the patients, 44.3% showed extrarenal infiltration into bone marrow, liver, spleen, central vervous system, lung and skin. Neoplastic cells express CD20, CD79a, PAX-5, and MUM1+, and were CD10-negative. Available follow-up data showed a median survival of 21 months after diagnosis. Extrarenal involvement is a significant and independent predictor of mortality with a hazard ratio of 4.975 (95% confidence interval:1.38, 17.88) after controlling for age and gender. Serum creatinine, age, sex, and infiltration of intrarenal arteries or veins did not affect survival. Conclusion: Kidney IVLBCL is a rare disease that is unexpectedly diagnosed by kidney biopsy, presenting with fever, anemia, mild AKI, and proteinuria. Median survival is 21 months and extrarenal involvement is associated with worse outcome.

Indexed as

B-lymphocytesintravascularkidney lymphomaprognosisproteinuria

Identifiers

PMID36938088
PMCPMC10014346
OpenAlexW4311424211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.